BioPharmSignal logoBioPharmSignal

Biotech News

Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

Hyperfine (HYPR)HyperfineFDA / regulatory

This newest software delivers improved image quality across Swoop system sequences, a more intuitive scanning experience, and new foundational isotropic imaging designed to strengthen the clinical utility of portable MRI. GUILFORD, Conn. --(BUSINESS WIRE)--Aug. 20, 2026-- Hyperfine, Inc.

Related news

HYPRHyperfine2026-10-22 12:15 EST

Hyperfine Advances International Swoop System Model 2 Rollout and Highlights the Role of Portable MRI in Brain Health Awareness

HYPRHyperfine2026-09-15 12:15 EST

Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents

VTAKCatheter Precision2026-09-02 20:15 EST

Flyte Secures International Approval to Launch Private Aviation Service Across The Bahamas and Caribbean

ANGOAngioDynamics2026-10-21 12:30 EST

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

ICUSeaStar Medical2026-10-07 12:16 EST

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

JNJJohnson & Johnson2026-09-21 14:33 EST

European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

ADPTAdaptive Biotechnologies2026-09-17 12:00 EST

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

ICCMIceCure Medical2026-10-20 11:55 EST

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

XAIRBeyond Air2026-08-31 12:00 EST

Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

FEMYFEMASYS2026-08-19 13:00 EST

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

View all latest news

Hyperfine

Portable Brain MRI Company Hyperfine develops the Swoop portable magnetic resonance brain-imaging system for use at the patient’s bedside and in settings without conventional MRI infrastructure. Low-Field Imaging Platform Swoop uses low-field magnetic resonance and can be moved through hospitals, reducing the logistical burden of...

Recent company news

HYPRHyperfine2026-10-22 12:15 EST

Hyperfine Advances International Swoop System Model 2 Rollout and Highlights the Role of Portable MRI in Brain Health Awareness

HYPRHyperfine2026-10-08 11:30 EST

Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026

HYPRHyperfine2026-10-08 11:30 EST

Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million

HYPRHyperfine2026-09-28 12:15 EST

Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets

HYPRHyperfine2026-09-15 12:15 EST

Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents

Stock data

Close
0.75 USD
Market cap
148.91M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States